High-yield points
- Neonates are different, not defective:
- Vitamin K-dependent factors are 40–60% of adult levels, and the PT and aPTT run long.
- Most values reach near adult by 6 months.
- Use age- and analyzer-specific ranges .
- Before blaming the patient, exclude the sample: a difficult draw, an under-filled tube or a high hematocrit .
- An isolated long aPTT with no bleeding history may be factor XII deficiency. Mucosal bleeding with normal labs suggests VWD .
- An infant with ICH and a long PT: think late VKDB. Ask about vitamin K .
- Reversal:
- Warfarin: vitamin K + 4F-PCC.
- Heparin: protamine 1 mg/100 U.
- Enoxaparin: protamine 1 mg/mg within 8 hours.
- Dabigatran: idarucizumab.
- Xa inhibitors: PCC or andexanet.
- Antiplatelets: platelets only if operating .
- Intraoperative bleeding:
- Run a goal-directed protocol: FFP 15–20 mL/kg, platelets 10 mL/kg (keep above 50,000), and early fibrinogen replacement.
- Give TXA for major cranial surgery.
- Keep rFVIIa as a last resort .
Landmark papers
- Goobie et al., Anesthesiology 2011: a double-blind, placebo-controlled trial in 43 children having craniosynostosis surgery. TXA cut blood loss (65 vs 119 mL/kg) and transfusion (33 vs 56 mL/kg) .
- PATCH (Baharoglu et al., Lancet 2016): a randomized trial in adults. Platelet transfusion for antiplatelet-associated ICH without surgery increased death or dependence (adjusted OR 2.05) .
- NCS/SCCM guideline (Frontera et al., Crit Care Med 2016): an adult guideline for reversal of antithrombotics in intracranial hemorrhage, the source of the reversal doses in this topic .
Pediatric neurosurgical bleeding is unforgiving: blood volumes are small, the skull is closed, and an inherited bleeding disorder may first show itself in the operating room. Neonates and infants are at highest risk. Their hemostatic system is immature, and an underlying inherited disorder may not yet have been diagnosed . Read infant coagulation tests against age-appropriate norms. Know the common anticoagulants and their antidotes, and have a plan for intraoperative coagulopathy.
Normal physiology: developmental hemostasis
- Cell-based model :
- Primary hemostasis: injured endothelium, von Willebrand factor (VWF) and platelets interact through platelet adhesion, activation and aggregation.
- Secondary hemostasis: initiation on tissue factor-bearing cells, amplification, then propagation, a burst of thrombin generated on activated platelets.
- Balance: fibrinolysis and the natural anticoagulants (antithrombin, proteins C and S) keep the system balanced.
- Neonates are "balanced but different": procoagulant and anticoagulant factors are both low at birth, so hemostasis is functionally balanced . Children are generally not at higher bleeding risk than adults .
- Neonatal levels compared with adults :
- Vitamin K-dependent factors (II, VII, IX, X): 40–60% of adult levels at birth. They normalize by 9–12 months. Factor IX matures last, so mild hemophilia B is hard to diagnose in infancy.
- Contact factors (XI, XII, prekallikrein, HMWK): low until about 6 months.
- Factor VIII and VWF: normal or increased. VWF has extra ultra-large multimers, which enhance primary hemostasis.
- Fibrinogen and factor V: normal or slightly low. Fetal fibrinogen forms weaker clots.
- Anticoagulants: antithrombin and protein C are about 50% of adult levels, and protein S 30–40%.
- Maturation:
- Most components reach near-adult values by 6 months, in both term and preterm infants. Preterm infants mature faster after birth .
- Bleeding times stay longer than adult values until about age 10 .
Lab values: normal vs. abnormal
- PT and aPTT are physiologically prolonged in neonates compared with adult ranges .
- Use age- and analyzer-specific reference ranges. Neonatal and pediatric reference values differ between analyzer and reagent systems, so each laboratory must set its own .
- Do not "correct" a normal neonatal aPTT with plasma.
- Rule out sampling artifact first:
- A difficult draw without free flow, or an under-filled tube, falsely prolongs the PT and aPTT.
- So does a high hematocrit (common in neonates), because the citrate ratio is off. Adjust the citrate for hematocrit.
- Misreading these results leads to unnecessary tests, plasma and procedure delays .
- Thresholds used for "coagulopathy" in pediatric severe TBI:
- Platelets below 100,000/mm³, INR above 1.2, or aPTT above 36 s.
- By these criteria, 42.8% of children with isolated severe TBI were coagulopathic, rising with severity (88.6% at head AIS 5) .
- Screening patterns :
- Normal INR, aPTT long or variable: hemophilia A or B, factor XI deficiency, some types of VWD, or factor XII deficiency. Mild deficiencies can give a normal aPTT. Factor XII deficiency prolongs the aPTT but usually causes no bleeding.
- Normal PT/aPTT with mucosal bleeding: suspect VWD or a platelet disorder.
- PFA-100: a screen for primary hemostasis. It is invalid with marked anemia, polycythemia or thrombocytopenia.
Congenital coagulopathies
- Hemophilia A: factor VIII deficiency, X-linked, 1 in 5,000 males. It causes delayed, joint, muscle and surgical bleeding, and newborn intracranial hemorrhage .
- Hemophilia B: factor IX deficiency, about 1 in 25,000 males .
- Management of hemophilia follows the World Federation of Hemophilia guidelines, with factor replacement planned with hematology .
- Factor XI deficiency ("hemophilia C"): about 1 in 100,000. Bleeding varies from none to severe CNS bleeding .
- Von Willebrand disease :
- The most common inherited bleeding disorder, affecting 0.1–1%.
- Types: type 1 (quantitative, 70–80%), type 2 (qualitative, 10–20%) and type 3 (near-absent VWF, 1–3%).
- Presentation: mucosal bleeding, with screening tests that are often normal.
- Surgery: the 2021 guidelines cover desmopressin trials and VWF and factor VIII target levels for major surgery .
- Syndromes with bleeding tendencies (relevant to craniofacial and spine practice):
- Noonan syndrome (factor deficiencies and platelet dysfunction).
- 22q11 deletion.
- Ehlers–Danlos and Marfan syndromes.
- Alagille syndrome .
Acquired coagulopathies
- Vitamin K deficiency bleeding (VKDB) :
- Timing: early (first 24 hours), classic (days 2–7) or late (2 weeks to 6 months, peaking at 3–8 weeks).
- Risk factors for late VKDB: exclusive breastfeeding and cholestasis.
- Late VKDB: surveillance in Asia and Europe found 4.4–72 per 100,000 live births. It is often intracranial: 82% of cases in Thai surveillance.
- Prevention: all newborns should receive vitamin K. Intramuscular prophylaxis reduces all three types.
- Neurosurgical red flag: an infant with spontaneous intracranial hemorrhage and a prolonged PT should prompt you to ask whether vitamin K was given.
- TBI-associated coagulopathy: common in children (see above). It was associated with brain contusions and lacerations, low GCS and ISS ≥ 16 .
- Other causes :
- Liver disease, which moves from a rebalanced state to bleeding.
- Renal failure (platelet dysfunction).
- Acquired von Willebrand syndrome from high shear (for example, cardiac lesions and devices).
- Cyanotic heart disease with polycythemia.
- Dilution and hyperfibrinolysis during massive bleeding.
Common medications and their reversal
The doses below come from the Neurocritical Care Society/SCCM guideline for antithrombotic-associated intracranial hemorrhage. It is an adult guideline, so confirm pediatric weight-based dosing with pharmacy and hematology .
- Warfarin (vitamin K antagonist):
- Treatment: vitamin K IV, plus 4-factor PCC (weight- and INR-based) in preference to FFP.
- Monitoring: recheck the INR 15–60 minutes after PCC, then every 6–8 hours.
- Avoid rFVIIa for warfarin reversal .
- Unfractionated heparin: protamine 1 mg per 100 units of heparin given over the previous 2–3 hours (maximum single dose 50 mg). If the aPTT stays prolonged, repeat 0.5 mg per 100 units .
- Enoxaparin (LMWH): protamine 1 mg per 1 mg of enoxaparin if it was given within 8 hours, or 0.5 mg per 1 mg if within 8–12 hours (maximum 50 mg). Protamine only partially reverses LMWH .
- Direct oral anticoagulants in children:
- Rivaroxaban is used in children with VTE. In EINSTEIN-Jr (500 children aged 0–17), recurrent VTE occurred in 1% with rivaroxaban vs. 3% with standard anticoagulation .
- Dabigatran reversal: idarucizumab 5 g IV . In adults it reversed dabigatran by a median of 100%, with procedures starting at a median of 1.6 hours .
- Factor Xa inhibitors (rivaroxaban, apixaban):
- 4F-PCC or activated PCC (aPCC) 50 U/kg, plus activated charcoal if ingested within 2 hours .
- Andexanet alfa reduced anti-Xa activity by 92%, with good hemostasis in 82%. Its trial population averaged 77 years old, and there are no pediatric data .
- Antiplatelet agents (aspirin, ADP inhibitors) :
- No surgery planned: do not transfuse platelets.
- Neurosurgery planned: transfuse platelets, using platelet-function testing where available.
- Desmopressin: consider a single dose of 0.4 µg/kg IV.
- Why the caution: in the adult PATCH trial, platelet transfusion for antiplatelet-associated ICH without surgery increased death or dependence (adjusted OR 2.05) .
- Thrombolytics (e.g., tPA): cryoprecipitate, then add more if fibrinogen is below 150 mg/dL. TXA or aminocaproic acid is an alternative .
Emergent management of coagulopathy during surgery
- Call for help early. Activate the massive hemorrhage protocol with goal-directed (lab- or viscoelastic-guided) resuscitation, and involve anesthesia and hematology .
- Treat what you measure: standard labs plus viscoelastic testing (TEG/ROTEM), where available. Age-specific triggers are still poorly defined .
- Components :
- Plasma (FFP) 15–20 mL/kg:
- Historically given for ongoing bleeding with INR and aPTT above 1.5× normal.
- Dose by weight and the desired correction.
- Plasma is a poor way to raise a low fibrinogen.
- Platelets 10 mL/kg. Expert consensus keeps the count above 50,000/µL during ongoing traumatic bleeding. Platelets carry the highest risk of transfusion reactions of any blood product.
- Fibrinogen: cryoprecipitate or fibrinogen concentrate.
- Fibrinogen is the first factor to fall to critical levels in major bleeding, through dilution and hyperfibrinolysis.
- In 1,948 children in pediatric trauma registry (TQIP) data, cryoprecipitate during massive transfusion was associated with lower 24-hour mortality.
- Fibrinogen concentrate is increasingly used, and cryoprecipitate has been withdrawn from most European countries.
- Tranexamic acid (TXA):
- Craniosynostosis trial (43 children): a 50 mg/kg load, then 5 mg/kg/h, cut blood loss (65 vs. 119 mL/kg) and transfusion (33 vs. 56 mL/kg) .
- Lower-dose protocol: a load of 6.4 mg/kg, then 2–3 mg/kg/h, targets effective plasma levels. It still needs clinical confirmation .
- Prothrombin complex concentrate (PCC):
- It is the first choice for warfarin reversal . Its use in children's hospitals is rising (1.3 to 4.6 per 10,000 encounters, 2015–2020), mostly in emergent or surgical settings unrelated to anticoagulant reversal .
- There is no pediatric evidence yet on efficacy, safety or dosing outside reversal .
- Recombinant factor VIIa (rFVIIa):
- Off-label rescue only. In a registry of 388 children, median age 12 months:
- Median first dose was 114 µg/kg.
- Blood product use fell afterward.
- 5.4% had thromboembolic events, and 28-day mortality was 27% .
- Because of thrombotic risk, current (cardiac surgery) guidelines advise against using it as rescue therapy. Pediatric noncardiac evidence is insufficient to recommend it .
- It is not for warfarin reversal .
- Correct acidosis: in the rFVIIa registry, pH before the dose independently predicted both response and 28-day mortality .
Related topics
- Estimating Blood Volume: allowable blood loss and transfusion planning.
- Perioperative Risk: overall risk assessment.
- Abusive Head Trauma: bleeding disorders in the differential of infant hemorrhage.
- Hereditary Vasculopathies: connective-tissue disorders with bleeding tendency.
- Spinal Epidural and Subdural Hematomas in Children: coagulopathy-related spinal bleeding.
- Craniopagus Twins: separation of conjoined twins.
References
- Erdoes G, Goobie SM, Haas T, et al. Perioperative considerations in the paediatric patient with congenital and acquired coagulopathy. BJA Open 2024;12:100310. doi:10.1016/j.bjao.2024.100310. PMID 39376894. verified
- Gorio C, Molinari AC, Martini T, et al. Hemostasis laboratory diagnostics in newborns. J Clin Med 2025;14(14):5068. doi:10.3390/jcm14145068. PMID 40725765. verified
- Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70(1):165–172. PMID 3593964. verified
- Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72(5):1651–1657. PMID 3179444. verified
- Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost 2006;95(2):362–372. doi:10.1160/TH05-01-0047. PMID 16493500. verified
- Talving P, Lustenberger T, Lam L, et al. Coagulopathy after isolated severe traumatic brain injury in children. J Trauma 2011;71(5):1205–1210. doi:10.1097/TA.0b013e31820d151d. PMID 21427617. verified
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046. PMID 32744769. verified
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021;5(1):301–325. doi:10.1182/bloodadvances.2020003264. PMID 33570647. verified
- Araki S, Shirahata A. Vitamin K deficiency bleeding in infancy. Nutrients 2020;12(3):780. doi:10.3390/nu12030780. PMID 32187975. verified
- Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med 2016;44(12):2251–2257. doi:10.1097/CCM.0000000000002057. PMID 27858808. verified
- Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020;7(1):e18–e27. doi:10.1016/S2352-3026(19)30219-430219-4). PMID 31699660. verified
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med 2017;377(5):431–441. doi:10.1056/NEJMoa1707278. PMID 28693366. verified
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380(14):1326–1335. doi:10.1056/NEJMoa1814051. PMID 30730782. verified
- Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016;387(10038):2605–2613. doi:10.1016/S0140-6736(16)30392-030392-0). PMID 27178479. verified
- Goobie SM, Meier PM, Pereira LM, et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology 2011;114(4):862–871. doi:10.1097/ALN.0b013e318210fd8f. PMID 21364458. verified
- Lutmer JE, Mpody C, Sribnick EA, et al. Prothrombin complex concentrate utilization in children's hospitals. J Pediatr Intensive Care 2023;12(3):219–227. doi:10.1055/s-0041-1731686. PMID 37565019. verified
- McQuilten ZK, Barnes C, Zatta A, et al. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012;129(6):e1533–e1540. doi:10.1542/peds.2011-2561. PMID 22641758. verified
Verification (2026-11-03): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. PubMed lists no DOI for references 3 and 4. Numbers were checked against PubMed abstracts and, where noted, full texts:
- Reference 1 (open-access full text, PMC11456917): developmental physiology, the inherited and acquired disorder tables and prevalences, the FFP, platelet, fibrinogen, cryoprecipitate, PCC, rFVIIa and TXA statements.
- Reference 2 (PMC12295540): neonatal factor levels, maturation ages and sampling artifacts.
- Reference 9 (PMC7146284): VKDB timing, incidence and the 82% intracranial figure.
- Reference 10: the reversal doses, from the executive summary on the publisher's site.
Caveats: reference 10 is an adult guideline, and its fixed adult doses (for example, vitamin K 10 mg and idarucizumab 5 g) are not pediatric doses. References 12–14 studied adults. No pediatric dose for vitamin K, PCC or andexanet is given here, because none was verified. Specific neonatal PT/aPTT numbers are omitted on purpose, because ranges depend on the analyzer . The original Andrew tables could not be accessed. The FFP and platelet volumes in reference 1 come from a viscoelastic-guided cardiac algorithm and are standard practice, not trial-derived thresholds for neurosurgery.